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We have shown a positive correlation between serum PTH concentrations, parathyroid gland weights, and skeletal histology in primary hyperparathyroidism," and Ellis and Peart24 have shown a similar correlation between gland weights and skeletal histology in patients with renal failure. It is difficult to obtain comparable data on parathyroid gland weights after renal transplantation, though we have some necropsy data25 suggesting that about half the allograft recipients who die with a functioning graft in situ 12 months or more after transplantation have macroscopically enlarged parathyroid glands.
The reason why parathyroid enlargement and hypersecretion persist in some patients but not in others is unknown. The abnormalities in our patients were mild and at the time of writing no allograft recipient had undergone parathyroidectomy.
Introduction
Acetylation is the metabolic pathway through which drugs such as hydrallazine,l isoniazid,2 dapsone,3 phenelzine,4 and many sulphonamides 5 are inactivated. Acetylation rates are bimodally distributed within populations because of a genetic polymorphism.6 Adverse effects from hydrallazine,7 isoniazid,8 dapsone, and phenelzine4 are commoner in patients who are phenotypically "slow" acetylators, in whom the slower rates of elimination are presumed to lead to a persistence of the drug in the body. In particular, the development of circulating antinuclear antibodies (A.N.A.) during treatment with hydrallazine is more common in such patients, and clinical evidence of hydrallazine-associated systemic lupus erythematosus (S.L.E.) is apparently confined to those with the "slow" acetylator phenotype. 7 Procainamide also undergoes extensive acetylation in man,9 and this may be under polymorphic control.' 0 Prolonged treatment with procainamide is associated in some patients" with the development of circulating A.N.A. which may be accompanied by a syndrome clinically resembling S.L.E." 1' We have tried to establish whether these changes are related to a person's capacity to acetylate drugs.
Patients and Methods
Twelve patients were investigated (see table). All had received procainamide for over three months, and none were given it during the determination of their acetylator capacity. In the seven patients in group 1 (see with procainamide but throughout the course of treatment were repeatedly negative for A.N.F. and L.E. cells. Case 9 was investigated only for the presence of A.N.F. Acetylator capacity was estimated from the elimination half life (t ) of isoniazid. Venous blood was taken for baseline measurements, and then isoniazid 10 mg/kg body weight (to the nearest 50 mg) was given by mouth after an overnight fast. Further blood samples were taken at 1 ., 3, 4 I-, and 6 hours. The patients remained seated throughout the t)-estimations. Plasma was stored at -20°C until analysed in duplicate for isoniazid by a spectrophotometric method. 13 The ti of isoniazid was calculated from least-squares regression analysis of the curve of plasma isoniazid concentration against time. Patients were taking various drugs at the time of the t I measurements but none are known to interfere with acetylation; they included digoxin, frusemide, warfarin, penicillin, phenindione, quinalbarbitone, guanethidine, and practolol.
Results and Discussion
In patients who developed A.N.A. no drug other than procainamide could be implicated. Moreover, in six of these patients withdrawal of the procainamide was followed by the disappearance of A.N.A. and in the seventh by a pronounced reduction in A.N.F. This suggests that no patient in group 1 had the spontaneous form of S.L.E.
The individual isoniazid t I values are shown in the table. Epidemiological studies under conditions identical with ours established that the antimode for isoniazid t' is 2-0-2-1 hours.14 On this basis five of the seven patients who developed A.N.A. during procainamide treatment were phenotypically "rapid" acetylators, while four of the five patients who did not develop A.N.A. were "slow" acetylators. The mean isoniazid t' in group 1 was 1-9 hours and in group 2 3-0 hours (P <0 05;
Wilcoxon's sign test). In respect of age, sex, diagnosis, and daily procainamide dosage, the two groups were reasonably comparable. The mean duration of treatment, however, was longer in group 1, which probably reflects the fact that therapeutic failure was responsible for the withdrawal of treatment in group 2. Patients in group 2 were also receiving fewer drugs concurrently with procainamide (see The present study, however, indicates that with procainamide, unlike hydrallazine, more-rapid rates of acetylation are associated with the development of A.N.A.
If our findings are confirmed they carry important implications. Firstly, they suggest that it might be possible to identify patients at risk of developing A.N.A. before they start treatment with procainamide. Secondly, they suggest that the immunological changes which may occur during long-term procainamide treatment may be caused not by the drug itself but by its acetylated metabolite N-acetylprocainamide. This metabolite is present in plasma from patients on procainamide at concentrations similar to those of the parent drug, and the amount excreted in the urine after procainamide administration is much greater in "rapid" acetylators." Finally, N-acetylprocainamide shows certain structural similarities to practolol (see fig.) 
SHORT REPORTS Haemolytic Anaemia due to Penicillin
A case of penicillin-induced haemolytic anaemia is described. Unusual features were that the penicillin was given in the usual therapeutic dose and only IgM antibodies were shown.
Case Report
A 22-year-old woman was admitted after a car accident in which she sustained a compound fracture of her frontal bone. She was given prophylactic antibiotics: an immediate dose of 600 mg of benzyl penicillin intramuscularly followed by 300 mg of benzyl penicillin q.d.s. for 24 hours, then 500 mg of phenoxy-methyl penicillin four times a day. Eight days after admission her haemoglobin had fallen from 13-7 g/dl on admission to 10 7 g/dl, her reti- 
